AML classifications
| AML . | WHO 2016 . | ICC . | WHO 2022 . |
|---|---|---|---|
| With defining genetic abnormalities∗ | PML::RARA (APL)† | RARA-R (APL) | PML::RARA (APL) |
| RUNX1::RUNX1T1† | RUNX1::RUNX1T1 | RUNX1::RUNX1T1 | |
| CBFB::MYH11† | CBFB::MYH11 | CBFB::MYH11 | |
| MLLT3::KMT2A | KMT2A-R | KMT2A-RE | |
| MECOM | MECOM-R | MECOM-RE | |
| BCR::ABL1 (provisional entity) | BCR::ABL1‡ | BCR::ABL1‡ | |
| NPM1 | NPM1 | NPM1 | |
| CEBPAbi | CEBPAbZIP | CEBPA‡ | |
| DEK::NUP214 | DEK::NUP214 other rare recurring translocations# | DEK::NUP214 | |
| RBM15::MKL1 | RBM15::MRTFA | ||
| Previous history of MDS, or MDS/MPN§ | MRC | MR | |
| disease defining | diagnostic qualifiers | disease defining | |
| Myelodysplasia-related with defining cytogenetic abnormalities§ | MDSk | ||
| complex karyotype | complex karyotype | complex karyotype | |
| -7/del(7q), del(5q)/t(5q), i(17q)/t(17p), -13/del(13q), del(11q), del(12p)/t(12p), idic(X)(q13) | del(5q)/t(5q)/add(5q),-7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), idic(X)(q13) | del5q or 5q, loss-7 or del7q or 7q loss, del11q, del12p or 12p loss, -13 or del13q, del17p or 17p loss or i17q, idic(X)(q13) | |
| balanced abnormalities | |||
| Dysplasia§ | >50% of cells of at least 2 lineages | ||
| With defining mutations§ | RUNX1 (provisional entity) | MDSgene | |
| ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 | ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 | ||
| TP53-mutǁ | TP53 | ||
| Without defining genetic abnormalities¶ | NOS | NOS | DD (defined by differentiation) |
| AML . | WHO 2016 . | ICC . | WHO 2022 . |
|---|---|---|---|
| With defining genetic abnormalities∗ | PML::RARA (APL)† | RARA-R (APL) | PML::RARA (APL) |
| RUNX1::RUNX1T1† | RUNX1::RUNX1T1 | RUNX1::RUNX1T1 | |
| CBFB::MYH11† | CBFB::MYH11 | CBFB::MYH11 | |
| MLLT3::KMT2A | KMT2A-R | KMT2A-RE | |
| MECOM | MECOM-R | MECOM-RE | |
| BCR::ABL1 (provisional entity) | BCR::ABL1‡ | BCR::ABL1‡ | |
| NPM1 | NPM1 | NPM1 | |
| CEBPAbi | CEBPAbZIP | CEBPA‡ | |
| DEK::NUP214 | DEK::NUP214 other rare recurring translocations# | DEK::NUP214 | |
| RBM15::MKL1 | RBM15::MRTFA | ||
| Previous history of MDS, or MDS/MPN§ | MRC | MR | |
| disease defining | diagnostic qualifiers | disease defining | |
| Myelodysplasia-related with defining cytogenetic abnormalities§ | MDSk | ||
| complex karyotype | complex karyotype | complex karyotype | |
| -7/del(7q), del(5q)/t(5q), i(17q)/t(17p), -13/del(13q), del(11q), del(12p)/t(12p), idic(X)(q13) | del(5q)/t(5q)/add(5q),-7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), idic(X)(q13) | del5q or 5q, loss-7 or del7q or 7q loss, del11q, del12p or 12p loss, -13 or del13q, del17p or 17p loss or i17q, idic(X)(q13) | |
| balanced abnormalities | |||
| Dysplasia§ | >50% of cells of at least 2 lineages | ||
| With defining mutations§ | RUNX1 (provisional entity) | MDSgene | |
| ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 | ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 | ||
| TP53-mutǁ | TP53 | ||
| Without defining genetic abnormalities¶ | NOS | NOS | DD (defined by differentiation) |
Although for WHO 2016 a blast count ≥ 20% is required for AML diagnosis, ICC requires ≥ 10% blasts; for WHO 2022, no minimal blast counts is required.
KMT2A-R, KMT2A rearrangements; KMT2A-RE, KMT2A with extended rearrangements; MECOM-R, MECOM rearrangements; MECOM-RE, MECOM with extended rearrangements; MPN, myeloproliferative neoplasm; MR, myelodysplasia-related; MRC, myelodysplasia-related changes; mut, mutation.
Major differences among classifications are highlighted in bold.
For WHO 2016 a blast count ≥ 20% is required; for ICC a blast count ≥ 10% is required;for WHO 2022 no blast count is required. Exceptions are indicated by the other symbols.
No minimal blast count required; exceptions to the WHO 2016 classification.
Blast count ≥ 20% is still required; exceptions to the ICC and WHO 2022 classifications.
A blast count ≥ 20% is still required.
A blast count ≥ 20% is required.
A blast count ≥ 20% is still required.
PRDM16::RPN1, NPM1::MLF1, KAT6A::CREBBP, RBM15::MRTFA, NUP98, and other partners, ETV6::MNX1, PICALM::MLLT10, FUS::ERG, RUNX1::CBFA2T3, and CBFA2T3::GLIS2.